Notes from the Field: Impact of a Mass Drug Administration Campaign Using a Novel Three-Drug Regimen on Lymphatic Filariasis Antigenemia — American Samoa, 2019
Weekly / May 29, 2020 / 69(21);656–657
Marisa A. Hast, PhD1,2; Aifili Tufa, PhD3; Tara A. Brant, MSc2; Lynette Suiaunoa-Scanlan, MPH4; Janet Camacho, MPH, MSN4; June Vaifanua-Leo, MD3; Keri Robinson, MPH2; Emily Dodd, MPH2; Ben Sili3; Loretta S. Lees3; Kimberly Y. Won, PhD2; Fara Utu3 (View author affiliations)View suggested citation
Views equals page views plus PDF downloads
Lymphatic filariasis is a debilitating and disfiguring mosquitoborne parasitic disease. As part of the Global Programme to Eliminate Lymphatic Filariasis, the World Health Organization (WHO) recommends at least five rounds of annual mass drug administration (MDA) in areas with endemic disease to reduce incidence and prevalence (1). Onward transmission is expected to end once community prevalence falls below 1% (1).
American Samoa, located in the southern Pacific Ocean, is the only U.S. territory with evidence of ongoing lymphatic filariasis transmission. After 7 years of MDA (2000–2006), the prevalence of lymphatic filariasis antigenemia in American Samoa declined from 16.5% to 2.3%, and MDA was stopped (2,3). In 2016, a household survey among 2,507 participants revealed that the prevalence of antigenemia had rebounded to 6.2%, and transmission was ascertained to be widespread across the territory (4). MDA was resumed in 2018 using a novel three-drug regimen of ivermectin, diethylcarbamazine, and albendazole, which has been shown to more effectively clear filarial larvae from the blood than the standard two-drug treatment of albendazole with diethylcarbamazine or ivermectin alone (5,6). This WHO-recommended three-drug regimen is anticipated to accelerate progress toward global elimination goals in areas without other filarial infections that would contraindicate the use of diethylcarbamazine (onchocerciasis) or ivermectin (loiasis).
During July 11–August 17, 2019, the American Samoa Department of Health (ASDOH) conducted a survey in collaboration with CDC and the Pacific Island Health Officers’ Association* to determine the effect of three-drug MDA on lymphatic filariasis prevalence in American Samoa. Households were selected from all 68 villages on the main islands of Tutuila and Aunu’u using systematic random sampling. Children aged 5–9 years and villages previously known to have high transmission rates were oversampled. Eligible household members aged ≥5 years with provision of informed consent were administered a questionnaire and provided a blood specimen for lymphatic filariasis antigen testing using the Alere filariasis test strip (Abbott). All participants who received antigen-positive test results were offered treatment.
ASDOH visited 1,865 households and enrolled 2,081 persons in the survey. A total of 47 participants with a positive antigen test for lymphatic filariasis were identified. Cases were geographically dispersed; however, a large proportion of cases were found along the western coast of Tutuila. By age, the antigen test positivity rate was 1.1% among children aged 5–9 years and 2.9% among household members aged ≥10 years. After adjusting for age and location, the overall prevalence of lymphatic filariasis antigenemia in American Samoa was estimated to be 2.7%. Adjusted prevalence of antigenemia was higher among males (4.8%) than among females (1.0%) (p<0.001), and this pattern was consistent across age groups (Figure). Differences in antigen prevalence by sex can be attributed in part to differences in MDA participation. Nonparticipation in the 2018 MDA was 35.2% among participants with positive antigen test results, compared with 22.2% among participants with negative antigen test results, and antigen prevalence among men aged >40 years who did not participate in the MDA was >10%.
These results indicate that lymphatic filariasis antigenemia has declined since 2016 but remains above the 1% WHO threshold in all age groups, suggesting that lymphatic filariasis transmission in American Samoa is ongoing. To interrupt transmission in this setting, American Samoa should consider following WHO recommendations (5) and continue annual three-drug MDA with appropriate monitoring of progress toward elimination until targets are met. Lymphatic filariasis control activities should target high-prevalence sectors of the population, including adult men, to ensure that this population is adequately covered in the future.
Corresponding author: Marisa A. Hast, firstname.lastname@example.org, 404-718-1109.
1Epidemic Intelligence Service, CDC; 2Division of Parasitic Diseases and Malaria, Center for Global Health, CDC; 3American Samoa Department of Health; 4Pacific Island Health Officers’ Association, American Samoa.
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2018. Wkly Epidemiol Rec 2019;94:457–72. https://www.who.int/publications-detail/who-wer9441-457-472external icon.
- World Health Organization Regional Office for the Western Pacific. The PacELF way: towards the elimination of lymphatic filariasis from the Pacific, 1999–2005. Manila, Philippines: World Health Organization Regional Office for the Western Pacific; 2006. https://iris.wpro.who.int/handle/10665.1/10966external icon
- Coutts SP, King JD, Pa’au M, et al. Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration. Trop Med Health 2017;45:22. CrossRefexternal icon PubMedexternal icon
- Sheel M, Sheridan S, Gass K, et al. Identifying residual transmission of lymphatic filariasis after mass drug administration: comparing school-based versus community-based surveillance—American Samoa, 2016. PLoS Negl Trop Dis 2018;12:e0006583. CrossRefexternal icon PubMedexternal icon
- World Health Organization. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. Geneva, Switzerland: World Health Organization; 2017. https://www.who.int/publications-detail/9789241550161external icon
- Thomsen EK, Sanuku N, Baea M, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis 2016;62:334–41. CrossRefexternal icon PubMedexternal icon
FIGURE. Prevalence of lymphatic filariasis antigenemia following mass drug administration using a novel three-drug* regimen, by age group and gender — American Samoa, 2019
* Ivermectin, diethylcarbamazine, and albendazole.
Suggested citation for this article: Hast MA, Tufa A, Brant TA, et al. Notes from the Field: Impact of a Mass Drug Administration Campaign Using a Novel Three-Drug Regimen on Lymphatic Filariasis Antigenemia — American Samoa, 2019. MMWR Morb Mortal Wkly Rep 2020;69:656–657. DOI: http://dx.doi.org/10.15585/mmwr.mm6921a3external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to email@example.com.